Physician Views: Can Sanofi, Regeneron's Dupixent quickly make its mark in adolescent atopic dermatitis?
Quickly established as a game changer for the treatment of moderate-to-severe atopic dermatitis in adults, Dupixent has now been approved by the FDA for use in adolescent patients aged between 12 and 17.
Sanofi has estimated that this cohort extends to a minimum of around 150,000 patients in the US, approximately half the size of the adult population. With key opinion leaders hinting that unmet need in adolescents is significant, adoption of Dupixent could be quick; and critical for Sanofi and Regeneron Pharmaceuticals' long-term growth aspirations as other mechanisms of action - including more convenient oral agents - vie to reach the market.
Our rapid-fire snap-poll is seeking insight on the potential speed of adoption of Dupixent in adolescent patients based on the following questions…
Q. How would you best describe the level of unmet need for an effective treatment for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17?
Q. The FDA has expanded approval of Dupixent (dupilumab) to include use in adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis that is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids and is administered by subcutaneous injection every other week following an initial loading dose. It can be given in a clinic or, for convenience, at home by self-administration after training by a healthcare professional.
Expanded approval is supported by Phase III efficacy and safety data showing that Dupixent demonstrated an approximate 66 percent improvement on the Eczema Area and Severity Index (EASI) versus baseline, compared to 24 percent for placebo. Furthermore, 24 percent of patients who received Dupixent achieved clear or almost clear skin compared to 2 percent of patients who received placebo, as measured by an Investigator’s Global Assessment (IGA) score of 0 or 1.
The safety profile of Dupixent in the adolescent trial was similar to the safety profile from studies in adults with atopic dermatitis, and consistent through 52 weeks. The most common adverse events were injection site reactions, eye and eyelid inflammation including redness, swelling and itching, pain in the throat (oropharyngeal pain) and cold sores in the mouth or on the lips.
How compelling a treatment option do you consider Dupixent to be for adolescent patients with moderate-to-severe atopic dermatitis?
Q. How do you anticipate your own utilisation of Dupixent in adolescent patients with moderate-to-severe atopic dermatitis to evolve?
Q. How would you best describe your clinical experience with using Dupixent for the treatment of adult patients with moderate-to-severe atopic dermatitis?
Q. Do you agree that the opportunity for future oral treatments for moderate-to-severe atopic dermatitis (i.e. potentially JAK inhibitors, for example) will be higher in adolescent patients versus adult patients?
Neither agree nor disagree
Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at email@example.com.
Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls. However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.